Overall five-year survival for patients with stage-II colon cancer averages 75% 
after surgery alone. However, some of these patients have poorer outcomes, 
similar to patients with stage-III disease. The proposed use of the Oncotype DX 
assay is to improve risk stratification for recurrence in stage-II colon cancer.